

# INTERNATIONAL SEARCH REPORT

International application No  
PCT/GB2006/002155

A. CLASSIFICATION OF SUBJECT MATTER  
INV. C07K14/605 A61K38/26  
ADD. A61P3/04

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
C07K A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

EPO-Internal, EMBASE, BIOSIS, WPI Data, Sequence Search

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	HOLZ G G ET AL: "Black widow spider alpha-latrotoxin: a presynaptic neurotoxin that shares structural homology with the glucagon-like peptide-1 family of insulin secretagogic hormones." COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY. PART B, BIOCHEMISTRY & MOLECULAR BIOLOGY. OCT 1998, vol. 121, no. 2, October 1998 (1998-10), pages 177-184, XP002408995 ISSN: 1096-4959	1-6, 8-24, 26-33, 37-42, 44-55, 57-59, 83-96
A	the whole document  ----- -/--	7,25, 34-36, 43,60

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

### \* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the International filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

24 November 2006

Date of mailing of the international search report

13. 03. 2007

Name and mailing address of the ISA/  
European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

Wiame, Ilse

## INTERNATIONAL SEARCH REPORT

International application No

PCT/GB2006/002155

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	DATABASE WPI Week 200447 Derwent Publications Ltd., London, GB; AN 2004-488426 XP002408998 -& CN 1 490 333 A (ZHONGKE YAGUANG BIOTECH CO LTD BEIJING) 21 April 2004 (2004-04-21)	1-6, 8-24, 26-33, 37-42, 44-55, 57-59, 83-96
A	abstract	7,25, 34-36, 43,60
X	----- DAKIN C L ET AL: "Oxyntomodulin inhibits food intake in the rat" ENDOCRINOLOGY, BALTIMORE, MD, US, vol. 142, no. 10, October 2001 (2001-10), pages 4244-4250, XP002226381 ISSN: 0013-7227	1-6, 8-24, 26-33, 37-42, 44-55, 57-59, 83-96
A	abstract	7,25, 34-36, 43,60
X	----- WO 2004/062685 A2 (IMP COLLEGE INNOVATIONS LTD [GB]; BLOOM STEPHEN ROBERT [GB]; GHATEI MO) 29 July 2004 (2004-07-29)	1-6, 8-24, 26-33, 37-42, 44-55, 57-59, 83-96
A	page 8, line 1 - page 11, line 21  the whole document	7,25, 34-36, 43,60
X	----- WO 2005/035761 A (COMPUGEN LTD [IL]; SHEMESH RONEN [IL]; KLIGER YOSSEF [IL]; NEVILLE LEW) 21 April 2005 (2005-04-21)	1-6, 8-24, 26-33, 37-42, 44-55, 57-59, 83-96
A	page 38, line 32 - page 40, line 31; claims 20,26,84,92,96; figure 4a  -----	7,25, 34-36, 43,60

# INTERNATIONAL SEARCH REPORT

International application No.  
PCT/GB2006/002155

## Box II Observations where certain claims were found unsearchable (Continuation of item 2 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
  
Although claims 85-91 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:  
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box III Observations where unity of invention is lacking (Continuation of item 3 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☒ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:  
  
1- 55 (all completely) and 57- 60, 83- 96 (all partially)

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. claims: 1-55 (all completely) and 57-60, 83-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37; and use thereof.

---

2. claims: 56,75-82 (all completely) and 57-60,84-96 (all partially)

A compound of general Formula (VI) as defined in claim 75, and use thereof.

---

3. claims: 61 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further amino acid from position 4 to 37 is substituted by an alternative amino acid; and use thereof.

---

4. claims: 62 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further two amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

5. claims: 63 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further three amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

---

6. claims: 64 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further four amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

7. claims: 65 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further five amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

8. claims: 66 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further six amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

9. claims: 67 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further seven amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

10. claims: 68 (completely) and 71-74, 84-96 (all partially)

## FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further eight amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

11. claims: 69 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further nine amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

12. claims: 70 (completely) and 71-74, 84-96 (all partially)

A compound of general Formula (I) as defined in claim 1, a compound of general Formula (II) as defined in claim 8, a compound of general Formula (III) as defined in claim 26, a compound of general Formula (IV) as defined in claim 35, a compound of general Formula (V) as defined in claim 37, a compound of general Formula (VI) as defined in claim 75; wherein a further ten or more amino acids from position 4 to 37 are substituted by an alternative amino acid; and use thereof.

---

13. claims: 83-96 (all partially)

A compound having the general Formula (VII) as defined in claim 83 wherein  
i) Lys(30) is acyl or PEG derivatised; or  
ii) the compound is a variant compound wherein any amino acid from position 1 to 37 is substituted with Lys to which an acyl or PEG side chain is derivatised.

---

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/GB2006/002155

Patent document cited in search report		Publication date	Patent family member(s)	Publication date
CN 1490333	A	21-04-2004	NONE	
WO 2004062685	A2	29-07-2004	AU 2004204369 A1	29-07-2004
			CA 2512939 A1	29-07-2004
			EP 1581248 A2	05-10-2005
			JP 2006515351 T	25-05-2006
			US 2006189522 A1	24-08-2006
WO 2005035761	A	21-04-2005	NONE	